打开APP

Titan治疗药物上瘾新药Probuphine或难通过FDA审核

  1. Probuphine
  2. Titan
  3. 药物上瘾

来源:生物谷 2013-03-20 14:51

2013年3月20日讯 /生物谷BIOON/ -- Titan公司研发的治疗类鸦片药物成瘾的药物probuphine的审批之路或再起波折。FDA工作人员指出,Titan公司提交的关于probuphine的研究数据不足以证明它的有效性,同时还对该药物的安全性提出了质疑。

2013年3月20日讯 /生物谷BIOON/ -- Titan公司研发的治疗类鸦片药物成瘾的药物probuphine的审批之路或再起波折。FDA工作人员指出,Titan公司提交的关于probuphine的研究数据不足以证明它的有效性,同时还对该药物的安全性提出了质疑。

Titan试图通过probuphine的三期研究数据来证明该药物相对于当前治疗药物上瘾的药物的优势,但是研究中仍然出现了8%的患者出现了副反应。同时,很多患者即便使用了probuphine,也需要再使用其他安慰剂来帮助治疗药物成瘾。

正是由于probuphine尚存在这么多问题,其上市之路还很漫长。(生物谷Bioon.com)

详细英文报道:

Titan Pharmaceuticals ($TTNP) looks like it's headed into choppy waters as it braces for an upcoming advisory committee review of its lead drug for opioid addiction. In an FDA review handed out to outside advisers in advance of their panel discussion and vote Thursday, staffers critiqued the efficacy data provided, the dose used in the pivotal study as well as its design, and the purported benefits and unanswered questions about the risks it presents to patients and their families.

Titan had trumpeted Phase III data purporting to show that Probuphine, an implant that releases buprenorphine over a period of 6 months, was better than a placebo at preventing addicts from using illicit opioids. Investigators also said it was noninferior to the approved therapy. But staffers picked apart that argument in the review.

"Even after allowing four months for engagement in treatment, only three Probuphine-treated patients were fully abstinent from opioids," said the staff. "Approximately 8% provided negative samples for at least 80% of tests."

"At the other end of the spectrum, about a quarter of Probuphine-treated patients were unable to provide even as few as 4 opioid-negative urine samples over the course of six months," the FDA staffers continued. "While the placebo group had even more discouraging results, supporting the conclusion that Probuphine does have an effect on drug use, overall, the response was not what one might hope for, given that the product ensures compliance with medication for six months. It prompts speculation that the dose is simply not high enough. … Potentially, Probuphine could deliver just enough buprenorphine to allow patients to continue to use illicit opioids without experiencing withdrawal when they stop."

Even if addicts get Probuphine, the staff notes, many will still need buprenorphine to manage their addiction, leaving the drug accessible to children--a threat the new therapy was supposed to avoid. A total of "40%-62% of Probuphine-treated patients required supplemental buprenorphine, and 11-12% required supplemental buprenorphine even after receiving a fifth implant."

There were problems with inserting the implants but the trial was too small to fully assess the risks, the FDA went on. And there were unanswered questions to consider about how long treatment would continue or what happens to patients after they stop treatment. And what happens to the addicts if they drop out of the program and never get the implants removed?

It's not unusual for a staff review to focus on unanswered questions or worries about efficacy and safety. Panelists are supposed to put developers through some tough questioning, to make sure the therapy lives up to expectations. But a barrage of criticisms like this may prove difficult to withstand, leaving Titan on shaky ground.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->